These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolution. Oshima S; Karrer EE; Paidhungat MM; Neighbors M; Chapin SJ; Fan RA; Reed MA; Wu K; Wong C; Chen Y; Whitlow M; Anderson FA; Bam RA; Zhang Q; Larsen BR; Viswanathan S; Devens BH; Bass SH; Higashi Y Protein Eng Des Sel; 2016 May; 29(5):159-67. PubMed ID: 26968452 [TBL] [Abstract][Full Text] [Related]
44. Turning the tide of lymphocyte costimulation. Zhu Y; Chen L J Immunol; 2009 Mar; 182(5):2557-8. PubMed ID: 19234146 [No Abstract] [Full Text] [Related]
45. CTLA4-Ig/CD86 interactions in cultured human endothelial cells: effects on VEGFR-2 and ICAM1 expression. Cutolo M; Montagna P; Soldano S; Contini P; Paolino S; Pizzorni C; Seriolo B; Sulli A; Brizzolara R Clin Exp Rheumatol; 2015; 33(2):250-4. PubMed ID: 25896473 [TBL] [Abstract][Full Text] [Related]
46. Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis. Ferraccioli GF; Bartoli E Clin Exp Rheumatol; 1998; 16(6):662-6. PubMed ID: 9844756 [No Abstract] [Full Text] [Related]
47. CTLA4Ig: bridging the basic immunology with clinical application. Bluestone JA; St Clair EW; Turka LA Immunity; 2006 Mar; 24(3):233-8. PubMed ID: 16546089 [TBL] [Abstract][Full Text] [Related]
48. Make or break for costimulatory blockers. Garber K Nat Biotechnol; 2004 Feb; 22(2):145-7. PubMed ID: 14755280 [No Abstract] [Full Text] [Related]
49. [The regulation of CTLA4-Ig in bone and cartilage destruction of rheumatoid arthritis]. Iwamoto N; Kawakami A Clin Calcium; 2015 Dec; 25(12):1817-23. PubMed ID: 26608857 [TBL] [Abstract][Full Text] [Related]
50. Abatacept mechanism of action: concordance with its clinical profile. Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048 [TBL] [Abstract][Full Text] [Related]
51. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A. Mukherjee S; Ahmed A; Nandi D J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440 [TBL] [Abstract][Full Text] [Related]
52. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Ruderman EM; Pope RM Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145 [TBL] [Abstract][Full Text] [Related]
53. Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin. Mukherjee S; Maiti PK; Nandi D J Leukoc Biol; 2002 Nov; 72(5):921-31. PubMed ID: 12429713 [TBL] [Abstract][Full Text] [Related]